- Home
- NCV vs PSNL Comparison
NCV vs PSNL Comparison
Compare NCV & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCV
- PSNL
- Stock Information
- Founded
- NCV 2003
- PSNL 2011
- Country
- NCV United States
- PSNL United States
- Employees
- NCV N/A
- PSNL N/A
- Industry
- NCV Finance Companies
- PSNL Medical Specialities
- Sector
- NCV Finance
- PSNL Health Care
- Exchange
- NCV Nasdaq
- PSNL Nasdaq
- Market Cap
- NCV 320.8M
- PSNL 321.1M
- IPO Year
- NCV N/A
- PSNL 2019
- Fundamental
- Price
- NCV $3.60
- PSNL $3.46
- Analyst Decision
- NCV
- PSNL Strong Buy
- Analyst Count
- NCV 0
- PSNL 4
- Target Price
- NCV N/A
- PSNL $6.81
- AVG Volume (30 Days)
- NCV 405.1K
- PSNL 893.0K
- Earning Date
- NCV 01-01-0001
- PSNL 11-06-2024
- Dividend Yield
- NCV 12.48%
- PSNL N/A
- EPS Growth
- NCV N/A
- PSNL N/A
- EPS
- NCV N/A
- PSNL N/A
- Revenue
- NCV N/A
- PSNL $87,489,000.00
- Revenue This Year
- NCV N/A
- PSNL $14.85
- Revenue Next Year
- NCV N/A
- PSNL $4.19
- P/E Ratio
- NCV N/A
- PSNL N/A
- Revenue Growth
- NCV N/A
- PSNL 24.05
- 52 Week Low
- NCV $2.84
- PSNL $1.12
- 52 Week High
- NCV $3.59
- PSNL $7.20
- Technical
- Relative Strength Index (RSI)
- NCV 61.98
- PSNL 34.39
- Support Level
- NCV $3.40
- PSNL $3.34
- Resistance Level
- NCV $3.57
- PSNL $5.40
- Average True Range (ATR)
- NCV 0.06
- PSNL 0.51
- MACD
- NCV 0.01
- PSNL -0.17
- Stochastic Oscillator
- NCV 100.00
- PSNL 4.84
About NCV Virtus Convertible & Income Fund of Beneficial Interest
Virtus Convertible & Income Fund is a diversified, closed-end management investment company. Its investment objective is to provide total return through a combination of capital appreciation and high current income. It intends to achieve the objective by investing in a portfolio of domestic convertible securities and non-convertible income-producing securities. Its portfolio of investments includes Software, the Internet, the Commercial Services sector in the form of Convertible Bonds and Notes, and Media, Oil, Gas & Consumable Fuels, and Entertainment sector in the form of Corporate Bonds and Notes.
About PSNL Personalis Inc.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.